R&D Projects


Platform for decision making in oncology diagnosis and treatment.

The main aim is to integrate clinical, metabolomic, and transcriptome sequencing data from liquid biopsies of breast cancer patients using next-generation sequencing (NGS) tools into a computer platform for medical decision-making regarding early diagnosis, classification, and pharmacological treatment options.

The project’s technological innovations include the development of new molecular signatures that combine metabolomic and transcriptomic data using NGS techniques that can predict how the disease will evolve compared to therapy and the development of a platform for the integration of clinical data from breast cancer patients. The ONCOPRECISE platform will incorporate deep learning and artificial intelligence systems, based on neural network models, which give it the ability to automatically design new molecular signatures for breast cancer prognosis and monitoring.

264 thousand

euros invested in the project


The platform will apply artificial intelligence to the design of molecular signatures that help to predict breast cancer.

The combination of the study of metabolomics and transcriptomics in liquid biopsies obtained through minimally invasive methods (from blood samples) is a powerful tool for monitoring patients and adapting therapies to the evolutionary state of the tumour, and is a further step forward for precision medicine.

To achieve the objectives


To ensure the success of the project, Atrys Health S.A. is collaborating with the company DATAGEN from Chile, the Hospital Médico Quirúrgico in Jaén, and the Medina Foundation.

This project has been co-funded by the European Regional Development Fund (ERDF) with the aim of promoting technological development, innovation, and quality research.

Financial blockers

Related projects



Reclasificación molecular para hallar biomarcadores útiles en enfermedades autoinmunes

Read more